

1 **Title page**

2 Title: The time is ripe to harmonize global acute febrile illness etiologic investigations

3 Running title: Harmonization of acute febrile illness investigations methods

4 Article category: Brief Report

5 Author names & institutional affiliations: José Moreira<sup>1,2</sup>, B. Leticia Fernando-Carballo<sup>3</sup>,

6 Camille Escadafal<sup>3</sup>, Sabine Dittrich<sup>3,4</sup>, Patrícia Brasil<sup>1</sup>, André M Siqueira<sup>1</sup>

7 Affiliations:

8 1.Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de  
9 Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

10 2. Instituto Nacional de Cardiologia, Departamento de Ensino e Pesquisa, Rio de Janeiro,  
11 Brazil

12 3. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

13 4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

14 Corresponding author: José Moreira MD Ph.D; e-mail: [jose.moreira@ini.fiocruz.br](mailto:jose.moreira@ini.fiocruz.br);

15 telephone number: +55 (21) 97035-8843; Laboratório de Pesquisa Clínica em Doenças Febris  
16 Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av.

17 Brasil, 4365 – Manguinhos, Rio de Janeiro, Brazil, CEP: 21040-360; Twitter: @j\_moreira\_

18

19

20

21

22

23

24

25

26 **Abstract**

27 We investigated the impact of considering different case definitions of fever as inclusion criteria  
28 among participants enrolling in an acute febrile illness investigation and observed that adopting a  
29 subjective assessment of fever regardless of specific fever cut-off value accounted for the  
30 diversity of clinical fever phenotypes and did not mischaracterize the febrile population.

31 **Keywords:** Antipyretic therapy; Fever; Acute febrile illness; Dipyrrone; Methodology

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **Text**

51 **Introduction**

52 Acute febrile illness (AFI) is a common reason for people seeking care and represents a range  
53 of infectious and non-infectious diseases, with wide variation by region of the globe [1]. AFI  
54 investigations aim to provide national and subregional epidemiology and infectious diseases  
55 surveillance and to inform treatment guidelines about empirical and pathogen-specific  
56 management algorithms to prioritize interventions and funding. Several AFI investigations  
57 have been conducted primarily in Southeast Asia, with few global initiatives in resource-  
58 constrained countries [2]. However, there is no standardized approach to conducting such  
59 studies, limiting the interpretation and comparability of study findings.

60 We were involved in a multinational project around fever host-biomarkers [3] and aimed to  
61 conduct a pilot study to inform the best criteria for our study site selection. We hypothesized  
62 that adopting a subjective or self-reported fever assessment as part of our inclusion criteria  
63 would increase the sensitivity threshold for a broad array of febrile clinical phenotypes rather  
64 than specifying a cut-off value for fever at presentation. Another hypothesis was that the  
65 recent antipyretic intake – largely available over-the-counter- would lower body temperature  
66 at arrival at the Emergency Departments (EDs).

67 **Methods**

68 We did a cross-sectional, study of patients presenting to two urban EDs (Unidade de Pronto  
69 Atendimento Manguinhos & Unidade de Pronto Atendimento Rocha Miranda) in Rio de  
70 Janeiro, Brazil, between October 28, 2018, and March 29, 2019. The study was conducted  
71 following the Declaration of Helsinki and the Brazilian National Ethics Research Committee  
72 and was approved in August 2018 (IRB approval no:70984617.9.0000.5262). We screened  
73 all consecutive non-severe patients who presented to the EDs over the study period and  
74 included those who reported fever  $\leq 7$  days regardless of temperature measured at the EDs.

75 Research assistants prospectively collected detailed information and interviewed participants  
76 or the primary caregivers to obtain data about the demographics, main chief complaint, vital  
77 signs, history of fever, peak measured temperature before arrival at the EDs (temperature  
78 maximum), the measured axillary temperature at the EDs, home administration of  
79 antipyretics, type/dose/timing of last administration, and tests performed at the EDs.  
80 Discharge diagnosis and treatment received after discharge was retrospectively collected by  
81 reviewing electronic medical records. The attending physician proposed the discharge  
82 diagnosis (not involved in the study), and its appropriateness was not re-evaluated. We used  
83 the following definitions: fever was subjectively identified by the participant at arrival at the  
84 EDs; antipyretics are mostly over-the-counter drugs that act on reducing body temperature  
85 usually with added analgesic effect, and were self-administered by the participants before  
86 seeking emergency care; adults those aged  $\geq 18$  years at recruitment, and non-severe AFI was  
87 an illness that was codified as blue or green according to the Manchester Triage System at  
88 EDs, which does not require hospital admission. We measured the axillary temperature at  
89 triage and estimated the magnitude of defervescence, considering the highest measured self-  
90 reported temperature before EDs arrival (Tmax). Suspected infection was defined as the  
91 initiation of any antimicrobial after an EDs visit.

## 92 **Statistical analysis**

93 Descriptive analysis was performed to characterize the distributions of several variables. A  
94 Chi-square test was used to compare categorical variables between study groups. Continuous  
95 variables were compared between the study groups using analysis of variance or the Kruskal-  
96 Wallis test if those were found to be normally or non-normally distributed, respectively. We  
97 dealt with missing data using the listwise deletion method (or complete case analysis).  
98 A logistic regression model was performed to ascertain the effects of recent antipyretic  
99 uptake on the likelihood that participants have an overt fever at EDs admission (i.e.,  $\geq 37.5$

100 °C). A 2-sided *p-value* less than 0.05 was considered statistically significant. All statistical  
101 analyses were performed using SPSS software (version 26, IBM, Chicago, Illinois, USA) and  
102 Tableau Desktop (version 2020.4.2, Tableau, Seattle, Washington, USA). The primary  
103 outcome was to investigate the impact of considering different case definitions of fever as  
104 inclusion criteria among febrile patients attending EDs.

## 105 **Results**

106 During the study period, we triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a  
107 history of fever at arrival at the ED, corresponding to a cumulative incidence of fever at EDs  
108 of 24 per 100 triaged patients over the five months. These 374 febrile patients constitute our  
109 study population, of whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature <  
110 37.5 °C, ≥ 37.5 °C, and no temperature measurement registered at arrival, respectively. The  
111 mean age was 30.6 [range: 0-84] years, adults (82.5%) and females (54.8%) predominated  
112 (Table). The median peak measured temperature before arrival at the ED was 38.8°C (38.0-  
113 39.0), and the median duration of fever was 1 [1-3] days.

114 Hundred ninety-eight febrile patients had a diagnosis of infection, with upper respiratory tract  
115 infection (42.4%) followed by undifferentiated febrile illness (15.7%) and urinary tract  
116 infection (14.6%) were the primary febrile syndromes (Supplementary Figure 1). Hundred  
117 thirty-one patients were prescribed any antibiotic after EDs visit, which beta-lactams (73/131,  
118 55.7%), quinolones (23/131, 17.5%) and macrolides (16/131,12.2%) were the classes most  
119 commonly prescribed. Patients who had temperature ≥ 37.5 °C at presentation were more  
120 likely to be diagnosed with an infection [76 (66%) vs. 116 (47%), crude OR: 2.2 (95% 1.4-  
121 3.5) and were prescribed antibiotic most frequently compared to those with temperature <  
122 37.5 °C [54 (65%) vs. 75 (48%), crude OR: 2 (95% 1.1-3.5)].

123 The site of infection varied by the height of temperature mensurated at arrival at EDs  
124 ( $p<0.001$ ). Patients who had a temperature < 37.5 °C at presentation were more likely to be

125 diagnosed with upper respiratory (31.6%) and urinary infections (15.4%) (Supplementary  
126 Figure 3). The most frequently etiology diagnostics recorded in those with temperature <  
127 37.5 °C at presentation were acute pharyngitis (20/248, 8%), followed by community-  
128 acquired gastroenteritis (19/248, 7.6%), uncomplicated urinary tract infection (16/248,  
129 6.4%), cutaneous abscess (14/248, 5.6%), and community-acquired pneumonia (9/248,  
130 3.6%).

131 In total, 249/374 (66.6% (95% 61.5-71.3)) subjects reported self-administering an  
132 antipyretic at home within a median of 2h [IQR 2-6] before EDs admission (24.1% of the  
133 febrile subjects did not recall prior antipyretics intake). Dipyron (72.2%) was the antipyretic  
134 drug most frequently administered, followed by acetaminophen (14.3%) and ibuprofen  
135 (6.3%). Most antipyretic takers consumed one class (85.9%), and the median number of  
136 doses taken was 2 [IQR 1-3]. Of these 249 subjects, 167/249 (67%) reported the last dose  
137 administered at a mean of 2 [2-5] hours before hospital presentation. Subjects who were  
138 treated with an antipyretic drug before arrival did not differ from untreated ones regarding the  
139 temperature at arrival at the ED visit ( $37 \pm 0.99$  vs.  $36.8 \pm 0.86$ ,  $p = 0.20$ ) or the documented  
140 T<sub>max</sub> before the ED arrival ( $38.8 \pm 0.79$  vs.  $38.4 \pm 0.60$ ,  $p = 0.29$ ).

141 The logistic regression model correctly classified 69.1% of the cases (Supplementary Table  
142 1). Males were 2.2 times more likely to exhibit overt fever at presentation than females [aOR:  
143 2.25, 95% CI: 1.19-4.25]. Recent antipyretic intake did not influence the pattern of fever at  
144 presentation [aOR:0.81, 95% CI:0.34-1.97].

## 145 Discussion

146 Our study suggests that considering a subjective/self-reported fever as an inclusion criterion  
147 rather than a specific fever cut-off value (i.e.,  $\geq 37.5$  °C) at presentation for AFI etiologic  
148 investigation results in a more inclusive study population and account for the diversity of  
149 clinical fever phenotypes that are usually seen in clinical practice. Specifically, sixty-six

150 percent of our cohort would not have been included if we restricted our inclusion criteria to a  
151 specific febrile cut-off, potentially impacting study recruitment and patient characterization.  
152 Almost half (47.8%) of febrile participants with temperature < 37.5 °C at presentation were  
153 prescribed at least one antibiotic, and their infections were mainly upper respiratory,  
154 justifying their inclusion in AFI studies. Next, our findings suggest that the ubiquitous  
155 administration of antipyretics (66.6%) observed in our setting did not influence the febrile  
156 presentation of patients attending the EDs evaluated.

157 We concur with others [2, 4] and argue that there is an urgent need to standardize AFI study  
158 protocols to make sure that we can compare results from different studies and pool their  
159 results to develop national, regional, or global burden of fever estimates. Such consensus in  
160 AFI research would allow better comparisons, translate evidence to practice, and inform  
161 treatment policy. A harmonized definition of fever would enable a more robust and consistent  
162 capture of different clinical phenotypes, including those conditions where overt fever occurs  
163 inconsistently, such as upper respiratory infections and uncomplicated urinary infections.  
164 Others [2] have suggested an adapted STRENGTHENING the reporting of OBSERVATIONAL studies  
165 in Epidemiology (STROBE) checklist for conducting and reporting AFI research.

166 In conclusion, we suggest harmonizing the case definition of fever in AFI research for a  
167 history of fever regardless of temperature cut-off would enable a complete picture of the  
168 different clinical fever phenotypes, thus improving our understanding of the global burden of  
169 febrile illness.

#### 170 **Author contributions**

171 JM: writing original draft, visualization, conceptualization. BC: Review and editing. CE:  
172 Review and editing. SD: review, editing. PB: conceptualization, writing, editing, supervision.  
173 AS: conceptualization, writing, editing, supervision

#### 174 **Funding**

175 The Biomarker for Fever-Diagnostic (BFF-Dx) study was funded by the Dutch, Australian,  
176 and UK governments.

### 177 **Transparency declaration**

178 The authors have no conflict of interest to declare.

179

### 180 **References**

181 1. Moreira J, Bressan CS, Brasil P, Siqueira AM. Epidemiology of acute febrile illness  
182 in Latin America. *Clin Microbiol Infect.* 2018; 24(8):827-835.

183 2. Rhee C, Kharod GA, Schaad N et al. Global knowledge gaps in acute febrile illness  
184 etiologic investigations: a scoping review. *PLoS Negl Trop Dis.* 2019; 13(11):  
185 e0007792.

186 3. Escadafal C, Geis S, Siqueira AM, et al. Bacterial versus non-bacterial infections: a  
187 methodology to support use-case-driven product development of diagnostics. *BMJ*  
188 *Glob Health.* 2020; 5(10)e:003141.2.

189 4. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and  
190 without evidence-based treatments. *BMC Med.* 2010; 18(1):287.

191

### 192 **Supplementary Tables**

193 Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in  
194 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October  
195 2018 – March 2019.

196 Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile  
197 patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March  
198 2019



199 **Supplementary Figures**

200 Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients  
201 attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

202 Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of  
203 infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,  
204 October 2018-March 2019

205 Supplementary Figure 3. Foci of infection according to the height of temperature  
206 mensurated at arrival in febrile patients attending Emergency departments in Rio de  
207 Janeiro, Brazil, October 2018-March 2019

208 Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated  
209 at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,  
210 October 2018-March 2019

211

212

213

214

215

216

217

218

219

220

221

222 Table. Baseline characteristics according to the height of temperature mensurated at arrival  
 223 in febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018-  
 224 March 2019  
 225

	<b>Total febrile population</b>	<b>History of fever but temperature &lt; 37.5 °C</b>	<b>History of fever and temperature ≥ 37.5 °C</b>	<b>p-value</b>
	<b>N= 374</b>	<b>N= 248</b>	<b>N= 115</b>	
<b>Characteristics</b>				
<b>Demographics</b>				
<b>Age (years), mean (±SD)</b>	31 (16)	32 (15)	28 (16)	<b>0.02</b>
<b>Missing</b>	3 (0.8)			
<b>Male, n- (%)</b>	169 (45.2)	103 (41.5)	62 (53.9)	<b>0.02</b>
<b>Temp at arrival, (°C), mean (±SD)</b>	37.08 (0.9)	36.55 (0.5)	38.24 (0.6)	<b>&lt;0.01</b>
<b>Missing</b>	12 (3.2)			
<b>Tmax (°C), mean (±SD)</b>	38.7 (0.7)	38.7 (0.69)	38.95(0.9)	0.12
<b>Missing</b>	268 (71.7)			
<b>Days of fever, mean (±SD)</b>	1.58 (17.4)	1.45 (21.2)	1.80 (3.2)	0.86
<b>Missing</b>	81 (21.7)			
<b>Degree of defervescence from Tmax, mean (±SD)</b>	1.70 (1.13)	2.16 (0.86)	0.78 (1.04)	<b>&lt;0.01</b>
<b>Diagnosis and management</b>				
<b>Diagnostic testing – n (%)</b>	76 (30.2)	42 (26.1)	32 (38.1)	0.05
<b>Recent antibiotic use – n (%)</b>	21 (12.2)	11 (9.6)	10 (18.9)	0.09
<b>Missing</b>	202 (54)			
<b>Recent antipyretic use – n (%)</b>	249 (66.6)	169 (87.1)	76 (90.5)	0.42
<b>Missing</b>	90 (24.1)			
<b>Antibiotic prescription – n (%)</b>	131 (53.0)	75 (47.8)	54 (65.1)	<b>0.01</b>

226 SD means standard deviation; Tmax higher temperature self-recorded at home before  
 227 emergency department visit; Recent antibiotic use was defined as any antibiotic for  
 228 systemic use started prior to emergency department visit. We excluded antibiotics for  
 229 systemic use that could also be used for the treatment of tuberculosis in patients with active  
 230 disease; Recent antipyretic was the use of any over-the counter antipyretic prior to  
 231 emergency department visit.

232 **Key messages**

- 233 • Fever is a common reason to seek care in patients attending urban Emergency  
234 Departments in Rio de Janeiro, Brazil
- 235 • Suspicion of infection is the underlying cause of fever in 53% of the febrile subjects,  
236 and the respiratory source is the main focus of infection
- 237 • The use of antipyretics among febrile patients attending urban Emergency  
238 Departments in Rio de Janeiro is ubiquitous, and dipyrone is the antipyretic of choice  
239 in our population. However, such use did not influence overt fever presentation in  
240 Emergency Departments
- 241 • Our findings are essential for designing fever etiology and question the value of  
242 adopting a specific temperature cut-off for fever at enrollment, as in many fever  
243 studies. We believe that a history of fever as part of the inclusion criteria is a good  
244 surrogate of unwellness and might be incorporated systematically in future fever  
245 studies.

246

247

248

## Appendix Table of Contents

This supplementary material has been provided by the authors to give readers additional information about their work.

### Supplementary Tables


- Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018 – March 2019.
- Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
- 

### Supplementary Figures

- Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019


Antibiotic class accordingly to the foci of infection in febrile patients attending ED in Rio de Janeiro, Brazil, October 2018 - March 2019



AEFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection


Supplementary Figure 2. Variability in antibiotic prescription according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Variability in antibiotic prescription according to the foci of infection in febrile patients attending ED in Rio de Janeiro, Brazil, October 2018 - March 2019




AEFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



AUI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019





Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018 – March 2019.

Variable		Adjusted Odds Ratio (95% CI)	p-value
Sex	Female	-	
	Male	2.25 (1.19-4.25)	<b>0.01</b>
Recent antipyretic use <sup>§</sup>	No	-	
	Yes	0.81 (0.34-1.97)	0.65
Age (years)		0.98 (0.95-1.00)	0.10
Time from fever onset (days)		1.00 (0.98-1.01)	0.97
Baseline Heart rate (beats/min)		1.050 (1.03-1.07)	<b>&lt; 0.05</b>

§Non-prescription antipyretic uptake reported by the participant before emergency department care

Dependent variable: proportion of febrile subjects with measured axillary temperature  $\geq 37.5$  °C at presentation

Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Presumed diagnosis by febrile syndrome	Number of presentations n/N (%)	Number of patients receiving an antibiotic prescription n/N (%)
<b>Gastrointestinal</b>		
Gastroenteritis	16/17 (94.11)	7/16 (43.75)
Gastritis	1/17 (5.88)	1/1 (100)
<b>Upper respiratory tract infection</b>		
Acute tonsillitis	34/84 (40.47)	34/34 (100)
Acute pharyngitis	22/84 (26.19)	5/22 (22.72)
Acute sinusitis	8/84 (9.52)	6/8 (75)
Common cold	5/84 (5.95)	0/5 (0)
Other upper respiratory tract infections	15/84 (17.85)	9/15 (60)
<b>Lower respiratory tract infection</b>		
Acute bronchitis and COPD exacerbations	3/17 (17.64)	2/3 (66.66)
Community-acquired pneumonia	9/17 (52.94)	8/9 (88.88)
Influenza	2/17 (11.76)	0/2 (0)
Other lower respiratory tract infections	3/17 (17.64)	3/3 (100)
<b>Skin and soft tissue infection</b>		
Cellulitis and abscesses	14/19 (73.68)	14/14 (100)
Other infection of the skin and soft tissue	4/19 (21.05)	4/4 (100)
Bacterial skin infection	1/19 (5.26)	1/1 (100)
<b>Urinary tract infection</b>		
Uncomplicated cystitis & pyelonephritis	28/29 (96.55)	25/28 (89.28)
Other urinary infection	1/29 (3.44)	1/1 (100)
<b>Acute undifferentiated febrile illness</b>		
Arboviruses	5/30 (16.66)	0/5 (0)
Unspecified febrile illness	6/30 (20)	4/6 (66.66)
Leptospirosis	2/30 (6.66)	2/2 (100)
Unspecified viral infection	15/30 (50)	1/15 (6.66)
Other	1/30 (3.33)	1/1 (100)

COPD stands for chronic obstructive pulmonary disease

